Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2, 2018. The document serves as a transaction notification regarding share allocations for Independent Non-Executive Directors for the service period of July 1, 2018, to September 30, 2018.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific equity transactions.
| Director | Instrument | Volume | Price | Transaction Date |
|---|---|---|---|---|
| Sir Philip Hampton | Ordinary Shares | 2,866.972 | £15.26 | 2018-10-31 |
| Mr Vindi Banga | Ordinary Shares | 471.003 | £15.26 | 2018-10-31 |
| Dr Vivienne Cox | Ordinary Shares | 348.132 | £15.26 | 2018-10-31 |
| Ms Lynn Elsenhans | ADSs | 1,045.912 | $39.42 | 2018-10-31 |
| Dr Laurie Glimcher | ADSs | 1,394.549 | $39.42 | 2018-10-31 |
| Dr Jesse Goodman | ADSs | 420.769 | $39.42 | 2018-10-31 |
| Ms Judy Lewent | ADSs | 468.857 | $39.42 | 2018-10-31 |
| Mr Urs Rohner | Ordinary Shares | 471.003 | £15.26 | 2018-10-31 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports the acquisition of notional shares and ADSs as part of standard director compensation arrangements.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions are described as "notional" acquisitions under share allocation arrangements.
Investor Verification Checklist
- Verify the total number of Ordinary Shares and ADSs allocated to directors for the Q3 2018 period.
- Confirm the transaction price of £15.26 per Ordinary Share and $39.42 per ADS against market prices on October 31, 2018.
- Review the company's annual report (Form 20-F) for the full impact of director share allocation plans on total equity compensation.
- Note that these are "notional" acquisitions, which may differ from actual share issuance or cash settlement depending on the specific plan rules.